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Abbreviations
ADCC  Antibody-directed cell-mediated cytotoxicity
Batf3  Also known as Jun dimerization protein 
p21SNFT
CVI  Cancer Vaccine Institute
c-FLIP  Cellular FLICE-like inhibitory protein
CDR-3  Complement-determining region no. 3
CPA  Cyclophosphamide
CRBN  Cereblon
CRP  C-reactive protein
DRiPs  Defective ribosomal products
EMA  Euopean Medical Agency
ERAP  Endoplasmic reticulum aminopeptidase
FDA  Food and Drug Administration
GD2  Ganglioside molecule
GDF15  Growth/differentiation factor 15
HDAC  Histone deacetylases
ICVI  Institute for Cancer Vaccines and 
Immunotherapy
IMiDs  Immunomodulatory drugs
Ire–xbp  Iron regulatory protein–x box protein
KIR  Killer cell receptors
LC–MS  Liquid chromatography–mass spectrometry
LDN  Low-dose naltrexone
LFA-1  Lymphocyte function-associated antigen-1
MART  Melanoma-associated antigen recognised by T 
cells
MHC  Major histocompatibility complex
MIC-1  Macrophage inhibitory cytokine 1
NDV  Newcastle disease virus
PAD  Peptidylarginine deiminase
PDE  Phosphodiesterase
PMN  Polymorphonuclear neutrophils
RFA  Radiofrequency ablation
RT  Radiotherapy
SiPTM  Stress-induced post-translational modifying
SLiPs  Short-lived proteins
SLP  Synthetic long peptide
TRP2  Tyrosinase-related protein 2
T-VEC  Talimogene laherparepvec
VIM  Vimentin
Introduction
This meeting was the third organised by the Cancer Vaccine 
Institute (CVI), now rebranded as the Institute for Cancer 
Vaccines and Immunotherapy (ICVI) to reflect the major 
input of non-vaccine-based immunotherapies in cancer treat-
ment. (The previous meetings were held in 2013 and 2015, 
all at the Royal Society premises, Carlton Terrace, London.)
A major driver of these meetings has been to access 
the overall impact of immunotherapy in conjunction with 
other modalities, such as radiotherapy and other potentially 
ablative therapies, e.g. radiofrequency ablation (RFA), in 
addition to the potential for chemotherapy to synergise with 
immunotherapy, as opposed to the previous perception that 
they were mutually incompatible.
The hallmarks of cancer were set in stone in a defini-
tive review by Hanahan and Weinberg, published in Cell in 
2000. It did not include any reference to any immune influ-
ence or perhaps even more surprisingly to the clear effect 
of chronic inflammation on the development of many com-
mon cancers. This was eventually corrected in 2011 when 
the effects of tumour-promoting inflammation and its effects 
over genome instability and mutation, as well as the effects 
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of downregulating cellular energetics and the extent tumours 
adapt to avoid immune destruction, were recognised. It was 
probably driven by the recognition of the first checkpoint 
inhibitor, ipilimumab (Yervoy) for melanoma, licensed by 
the FDA in the same year. Subsequently, the PD-1 check-
point inhibitors, pembrolizumab (Keytruda), nivolumab 
(Opdivo), have now been licensed for not only melanoma but 
also lung cancer. In addition, activity has been documented 
for these agents in 23 different cancer types, including recent 
approvals for head and neck cancer and bladder cancer. 
However, in spite of what can only be described as a revolu-
tion in cancer treatment, response rates are still relatively 
low and relapses common. This has inspired a major focus 
of research based on biomarkers and a search for predictors 
of response. Much of this has focused on the expression of 
PD-1 and PD-L1 and the likelihood of a response to PD-1 
inhibitors. Although a significant association was initially 
described, it is clear that in reality it is not that simple, with 
significant responses to PD-1 inhibitors being reported in 
PD-L1-negative individuals.
With this in mind, the symposium focused on how differ-
ent immunotherapies could be combined with at least addi-
tive clinical benefit, although many of these combinations 
involve enhanced toxicities, such as when ipilimumab is 
combined with Nivolumab. A major focus was the poten-
tial for a real synergy with chemotherapy, particularly when 
given at lower doses, as well as other agents which exert 
subtle immune modulatory effects.
The symposium involved several references to chemother-
apy agents, which when used at lower doses had a benefi-
cial effect on the immune response, especially when cancer 
vaccines were used. A number of agents were mentioned, 
including gemcitabine, but the most frequently referred to 
agent was cyclophosphamide, although there was a consid-
erable variation in the suggested doses and schedules used.
Cyclophosphamide (CPA) enhanced immune 
protocols
David Waxman (Boston University, Boston, USA), focused 
on CPA mechanisms of action, particularly in its role in met-
ronomic schedules. CPA depletes immune-suppressive T-reg 
cells and boosts cytokines that enhance the maturation of 
DCs as well as expand T cells with a memory phenotype. 
Using a murine glioma model, he showed that CPA given 
with a 6-day drug break activated innate immune activity 
which was more effective than more frequent delivery of 
CPA. After several cycles, long-term CD8+ T cells were 
induced, as well as activated NK cells. Non-responsive 
tumours were shown to lack IFN-αβ induction, suggest-
ing that poly I:C treatment may help in correcting this 
deficiency.
It is important to note that the dose used for the 6-day 
cycle was given at 140 mg/kg, which, based on body surface 
area, corresponds to a human equivalent dose of 11.4 mg/
kg. While this dose may seem high for humans, it is not 
high when considering the much more rapid elimination of 
cyclophosphamide in mice (t1/2 = 24 min in mice vs. t1/2 = 5 h 
in humans). Consistent with this difference in pharmacoki-
netics, there is a clear difference in optimal doses for cyclo-
phosphamide immune effects in humans, where doses of 
50–100 mg a day for 1 week on, followed by 1 week off, 
are able to suppress the T-reg response in patients. David 
Waxman also showed that cultivating autologous tumour 
cells with activated CPA, or with doxorubicin, can greatly 
enhance the immunogenicity of these cells when used as a 
vaccine. Several other speakers mentioned the beneficial use 
of CPA on T-reg function including Emily Webb (Univer-
sity of Southampton, Southampton, UK), Sandra Tuyaerts 
(Katholieke Universiteit (KU) Leuven, Leuven, Belgium), 
Thomas Nesselhut (Institute of Cell Therapy, Duderstadt, 
Germany) and Samir Khleif (Augusta University, Augusta, 
USA) who have used a single dose of CPA of 50 mg before 
vaccination, which is similar to that used before T-cell adop-
tive transfer therapy.
The use of CPA in priming the immune response and 
suppressing the regulatory network was a major focus in the 
final discussion section of the meeting, with support from 
many speakers and participants that the data for enhanc-
ing immune responses were overwhelming, although the 
dose and schedules were highly variable and that there were 
significant problems in extrapolating from mice to humans, 
particularly with regard dose. It was concluded that there is 
a real need to directly compare pre-treatment with 300 mg 
iv with weekly or 1 week on and 1 week off metronomic 
therapy with CPA.
Chemotherapy and myeloid‑derived 
suppressor cells (MDSCs)
The importance of MDSCs in the development and main-
tenance of cancer growth and the need to inhibit them to 
switch off their marked immunosuppressive effects were 
mentioned as a major topic by a number of speakers, includ-
ing Michael Shurin (University of Pittsburgh, Pittsburgh, 
USA), Viktor Umansky (Deutsches Krebsforschungszen-
trum, Heidelberg, Germany) and Cornelis Melief (Leiden 
University Medical Center, Leiden, Netherlands). M Shurin 
pointed out that MDSCs produced a range of oxidative mol-
ecules, which alters the TME. In particular, he pointed out 
that this degrades chemotherapies, such as doxorubicin, 
and that this effect needs to be protected to be effective as 
an anti-tumour agent. He presented a model using carbon 
nanotubes to encapsulate doxorubicin to aid delivery to the 
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tumour in a B16 cell model. He proposed that encapsulated 
drugs, such as Taxol, could target MDSCs in particular. In 
previous meetings, M Shurin had emphasised the benefit 
of low-dose and ultralow-dose chemotherapies in different 
models in addition to the benefit of low-dose radiotherapy 
schedules. It is speculated that the observed benefit of chem-
otherapy may largely come from its effect on the TME and 
suppression of MDSCs, in particular.
Rolf Kiessling (Karolinska Institutet, Stockholm, Swe-
den) also focused on the importance of reducing MDSCs 
and showed that anti-cytotoxic T-lymphocyte-associated 
antigen 4 (anti-CTLA4) antibodies can reduce the num-
bers of MDSCs and T-regs, and especially the numbers of 
monocyte MDSCs in responding patients. This leads to an 
increase in CD8 effector memory cells in long-term survi-
vors in patients with advanced melanoma. Viktor Umansky 
also focused on the importance of addressing MDSCs as a 
vehicle of immunosuppression, which is driven by chronic 
inflammation. He showed that there are two main types of 
MDSCs in humans, CD15+/CD14− polymorphonuclear 
neutrophils (PMN) MDSCs and CD15−/CD14+ mono-
cytic MDSCs. They all express PD-L1 and their activation 
is influenced by the TME-inducing cytokines and exosomes 
derived from the tumour. Importantly, he showed that silde-
nafil inhibits cGMP activity, which normally induces NO, 
which effects NO reduction in mice. This translates to a 
survival benefit mediated by CD8 T cells, which recover ζ 
(zeta)-chain expression, IL-2 production and proliferation of 
T cells. In a human phase II study in pre-treated melanoma 
patients, tadalafil (a PDE-5 inhibitor) induced stable disease 
in 3/12 patients, who showed higher numbers of CD8 and 
TILs in their metastases and both CD4 and CD8 cells in their 
peripheral blood, increased CD3ζ-chain expression.
Cornelis Melief reported on the need to address the 
MDSCs in the blood and tumour to enhance vaccine effec-
tiveness and that combining the HPV16-SLP vaccination 
protocol with chemotherapy (carboplatin and paclitaxel) 
gradually led to a reduction of MDSC and enhanced and 
sustained T-cell responses. He also mentioned that check-
point inhibitors could further enhance these effects.
Novel targets and strategies to reduce 
tumour immune suppression
Jorg Wischhusen (University of Würzburg, Würzburg, Ger-
many) presented his work on growth differentiation factor 
(GDF)-15 (MIC-1) as a tumour immune-suppressive factor 
and that it could be an effective target for treatment. It is a 
divergent member of the TGFβ family, expressed at high 
levels in the placenta, prostate and then in stressed tissues. 
However, high levels are seen in melanoma patients, where 
high levels are an independent predictor of poor survival. 
GDF-15 reduces binding of ICAM to lymphocyte function-
associated antigen-1 (LFA-1) thereby inhibiting adhesion 
to the endothelial cells. GDF-15 levels were also shown to 
predict poor response to anti-PD1 treatment. Data show-
ing that anti-GDF-15 antibodies can enhance the effects of 
immunotherapy in mouse models support further develop-
ment and translational studies in the clinic.
Samir Khleif reported on the ability of mutant genes, 
like KRAS, to influence the TME. Colorectal cancer patients 
with KRAS mutations have a greater number of T-regs. He 
presented data to show that FoxP3 expression correlated 
with mutant RAS and that if RAS is ‘knocked down’ there 
is a reduction in IL-10 and TGFβ. The practical application 
of this destruction is that ras signalling pathways can be 
targeted to enhance the immune response. He focused on 
the functional dichotomy in Class IA PI3K isoforms. The 
PI3Kδ (delta) was reported to be selective for T-reg function. 
A specific inhibitor of this pathway was shown to enhance 
the effectiveness of a tumour-specific vaccine by decreasing 
T-reg T cells and enhancing CD8 T cells. He then reviewed 
that CPA at low doses could also enhance this activity, 
which was the focus of his talk at the previous meeting.
Thomas Sayers (National Cancer Institute, Frederick, 
USA) reviewed his work on the molecular basis of apopto-
sis in tumours and the members of the TNF-related apop-
tosis-inducing ligand (TRAIL)-R family containing both 
pro- and anti-apoptotic receptors. Screening for agents that 
would sensitise tumour cells to apoptosis, he identified com-
pounds from the withanolide family (derived from Physalis 
peruviana). Members of this family sensitise the tumour 
cells to TRAIL and DR4 and DR5 signalling. In addition, 
some cancer cells were also sensitised by withanolides to 
undergo apoptosis in response to the viral mimetic poly-
(I:C). Mechanisms appear to depend on c-FLIP reduction 
by withanolides, which is a post-translational effect, there 
being no effect on gene expression. The relevant question 
to this meeting is ‘do these agents sensitise cells to become 
apoptotic when exposed to immunotherapy?’ In a murine 
B16 model he showed that the combination was superior to 
either agent alone but there is, as yet, no clinical translation 
to support this preliminary observation.
Other ways to enhance the response to immunotherapy 
with novel or repurposed drugs included the use of Zometa 
to enhance Vδ2+ γδ T-cell perforin-dependent cytotoxic-
ity and how this relates to bone metastasis control. Details 
of this mechanism were presented by Daniel Fowler (St 
George’s University of London, UK) who specifically 
reviewed the effect on both M1 and M2 macrophages look-
ing for a potential selective effect that could be exploited 
clinically.
Barbara Seliger (Martin-Luther-Universität, Halle-Wit-
tenberg, Germany) extensively reviewed the reasons why 
MHC class I surface expression is reduced in tumours. This 
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could be due to transcriptional, epigenetic and post-tran-
scriptional regulation of MHC class I antigens or compo-
nents of the antigen processing and presentation machinery. 
Furthermore, gemcitabine as well as IFN-γ have previously 
been reported to be able to reverse this impaired expres-
sion. She presented data that HDAC inhibitors can increase 
MHC class I expression in tumours of distinct origin. In 
addition, she showed the importance of not only the IFN-γ 
signalling pathway, in particular, the molecules JAK-1, JAK-
2, STAT-1 for constitutive, but also IFN-γ-inducible MHC 
class I expression. Structural alterations of JAK-2 in mela-
noma cells leading to reduced MHC class I APM expression 
and resistance to IFN-γ treatment were detected and overex-
pression of JAK-2 into JAK-2-deficient cells restored IFN-γ 
sensitivity and enhanced constitutive MHC class I surface 
expression in these cells.
Cancer vaccine updates
A major focus of this meeting was to review the latest in 
cancer vaccine development. Lisa Butterfield (University 
of Pittsburgh, Pittsburgh, USA) reviewed the enormous 
literature involving over 200 DC vaccine clinical trials in 
melanoma. Although the clinical responses are in the 5–10% 
range, there is no overall consistent effect and little correla-
tion to vaccine immune responses. Essentially, we do not yet 
really understand the best method of maturation or loading, 
route of injection, best dose, etc. She briefly reviewed two 
previous DC trials, namely the MART-1 peptide pulsed on 
immature DCs and second, the DCs loaded with MART-
1-expressing adenovirus. The main conclusion from these 
was that epitope spreading was associated with the best 
clinical responses, an effect which has also been reported 
with Dendreon’s Provenge studies. This suggests that target-
ing multiple antigens is better and IFNα may improve this 
effect. However, a multi-antigen-expressing adenovirus vec-
tor-transduced DC vaccine showed only 2 partial responses 
in 35 patients (neither of whom received IFNα). Microarrays 
of the DC vaccines, together with blood and tumour profiling 
studies, are being used to determine correlates of response to 
determine future combination therapies. There are currently 
five phase III and five phase II vaccines with checkpoint 
inhibitors (anti-PD-1) in progress.
This underscores a major ongoing trend, i.e. the use of 
PD-1 inhibitors in combination with other vaccines and 
immunotherapy agents to enhance clinical responsive-
ness. Whereas there is little to go on, in ways to opti-
mise DC-based vaccines, Brendon Coventry (University 
of Adelaide, Adelaide, Australia) reported that vaccine 
responses are least likely to occur when the C-reactive pro-
tein (CRP) level is high and respond much better when it 
is low. He has previously reported that this level fluctuates 
cyclically even in individual patients. Angus Dalgleish (St 
George’s University of London, London, UK) has previ-
ously reported that the only correlate of clinical outcome 
observed in a previous DC-based vaccine for advanced 
melanoma patients was that responders were the only ones 
not to have elevated inflammatory markers. This has given 
rise to measuring these markers so that vaccines are given 
at the lowest levels (B Coventry) or to the realisation that 
perhaps anti-inflammatory agents may prime for vaccine 
responses, which has previously been shown in murine 
models.
Victoria Brentville (Scancell Ltd, Nottingham, UK) 
gave an update on the ImmunoBody® platform-based DNA 
vaccines which can induce high avidity T-cell responses to 
tumour-associated antigens (TAAs). Epitopes are engineered 
into the CDR3 region of immunoglobulin G (IgG). This is a 
whole antibody including the Fc region, which is absolutely 
necessary for function. The first clinical product is SCIBI, 
which has three epitopes from gp100 and one from TRP2 
engineered into its CDR region. The vaccine alone has given 
a survival benefit in melanoma models (and patients), in 
combination with PD-1 antibodies, this effect is enhanced 
in murine models.
Their alternative approach depends on identifying suit-
able siPTMs and boosting them through a platform called 
moditope. This work has focused on the autophagy pathway 
for long-lived proteins which cause citrullination of argi-
nine by  Ca2+-dependent peptidylarginine deiminase (PAD) 
enzymes. This has led to the development of vimentin 
(VIM)-based citrullinated peptide-based vaccines that have 
been shown to be very effective in mouse models. A lead 
clinical target containing multiple such peptides is being 
developed.
Bernard Fox (Earle A Chiles Research Institute, Port-
land, USA) presented his data using a similar but different 
approach to creating a novel multivalent vaccine by disrupt-
ing the degradation of intracellular proteins by the ubiqui-
tin proteasome system. This also involves autophagosome 
products and is branded as the DRibbles vaccine, containing 
DRiPs (defective ribosomal products) and SLiPs (short-lived 
proteins), including TAAs. This involves blocking and stabi-
lising these agents and harvesting autophagosomes by mem-
brane disruption and fractionalisation to create an ‘autolo-
gous vaccine’. Pre-clinical work looked at the effect of these 
vaccines on the expression of γIFN in the draining lymph 
nodes, showing that the DRibbles approach was much better 
than a whole cell vaccine in enhancing γIFN expression.
Combining this approach with anti-OX40 antibodies 
enhanced protection in mice, which led to looking at an 
allogenic preparation of DRibbles for large-scale studies 
(DPV-001). A randomised study for stage III/IV NSCLC 
patients is underway with CPA being used as an immune 
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modulator. Combination with other checkpoint inhibitors 
(e.g. PD-1) is another obvious possibility.
It is also of relevance here to highlight the content of 
the winning poster presentation by Derin B Keskin (Har-
vard Medical School, Boston, USA). Previous methodolo-
gies for the prediction of peptide presentation have had 
limitations and were subject to certain biases. Derin B 
Keskin presented methodology based on high-resolution 
liquid chromatography–mass spectrometry (LC–MS/MS) 
which was used to identify HLA-allele-specific peptides. 
These peptides were used to train new algorithms which 
can be used to predict HLA-binding epitopes with more 
accuracy. This poster also detailed use of a relatively new 
technology (non-scale MS) which is being developed 
for the identification of neo-epitopes in tumour biopsy 
material.
Alan Melcher (Institute for Cancer Research, London, 
UK) reviewed the potential of oncolytic viruses to enhance 
the immune response. T-VEC, an HSV-1-modified agent 
expressing GM-CSF gene, has been licensed for intratu-
moural administration in melanoma and has been shown 
to induce regression of both injected and non-injected 
lesions. Once again, this effect has been enhanced by com-
bining it with checkpoint inhibitors. He also reviewed the 
potential for replication competent reovirus to enhance 
specific anti-tumour responses by making ‘cold’ tumours 
(low CD8+ TILs/PD-L1 expression) ‘hot’, leading to 
tumour regression when combined with PD-1 blockade.
This was a consistent theme of the meeting in that PD-1 
antibodies only work in less than 50% of the patients but 
they may be much more effective if tumours are primed 
with vaccines, etc. to make them ‘hot’.
Another theme of the meeting was the benefit of drugs 
that can immunomodulate the immune response and sev-
eral, such as CPA, gemcitabine and anti-inflammatories, 
have already been mentioned. Rajesh Chopra (Institute 
for Cancer Research, London, UK) reporting on the most 
effective immune modulators described the immunomodu-
latory drugs (IMiDs), which include Revlimid (lenalido-
mide) and pomalidomide. He reviewed the insight into the 
mechanisms of action following the discovery of the inter-
action with cereblon (CRBN) as a target for thalidomide. 
There are several areas for new agents from this work, 
such as targeting the unfolded protein response, such as 
the IRE–XBP-1 pathway. He also reviewed the importance 
of targeting the endoplasmic reticulum aminopeptidase-1 
(ERAP1) and -2 pathways, which can lead to more immu-
nogenic and larger peptides. Knockout ERAP1 mice gave a 
survival benefit over controls. This work is complimentary 
to that of C Melief, who has demonstrated the benefit of 
long HPV peptide-based vaccines clinically. There is an 
obvious potential for combination of these approaches in 
the future.
Neuroblastoma antibody therapy
Paul Sondel (University of Wisconsin, Madison, USA) has 
helped pioneer the use of antibodies to ganglioside mole-
cule-2 (GD2) in patients with neuroblastoma, which has taken 
20 years to develop phase III trials, leading to approval by the 
FDA and EMA. A component of this regimen is the combina-
tion with IL-2, which activates NK cells and GM-CSF, which 
activates neutrophils and monocyte/macrophages, all of which 
may be helpful via antibody-dependent cell-mediated cytotox-
icity (ADCC). Unfortunately, the treatment still does not work 
in some patients and attempts to develop a good biomarker, 
via killer cell receptors (KIR)/KIR–ligand genotyping, were 
described. A humanised anti-GD2 with IL-2 engineered at the 
Fc terminal has now been developed. In murine models, this 
can be enhanced by intratumoural delivery and anti-checkpoint 
inhibitors (anti-CTLA-4). Radiotherapy (RT) could enhance 
this effect when given prior to treatment.
Emily Webb is also investigating this approach for neu-
roblastoma and addressing the fact that relapse is common. 
Using animal models (NXS2) enhancement was shown with 
CPA, which depleted T-regs, as well as combining with 
anti-PD-L1 treatments. The outcome of these presentations 
strongly suggests an optimisation of anti-CD-2 antibody with 
CPA, IL-2 and anti-PD-L1 antibodies.
Combination antibodies
Combining antibodies was the focus of Holbrook Kohrt, who 
presented this approach at our previous meeting. Sadly, he died 
from the effects of haemophilia.
Ignacio Melero reviewed the potential of this approach 
using a car analogy: the need to take the foot off the break, 
step on the gas and pave the road. Interest is growing in alter-
native checkpoint blockade targets. He focused on anti-CD137 
that Holbrook had identified, and which is already known to 
enhance rituximab in multiple myeloma. In mice, he showed 
how a combination of anti-41BB (the murine homologue of 
CD137) with anti-PD-1 had anti-tumour effects. These effects 
were not observed in the Batf3-deficient mouse suggesting an 
importance of CD103+ dendritic cells. I Melero further dem-
onstrated an abscopal effect in mouse where treatment with 
radiotherapy in combination with anti-PD-1 led to response 
of distant lesions as well as locally treated lesions.
Practical aspects and future studies
It is now so clear that combination of these approaches 
should be more effective that singular approaches. Unfortu-
nately, this introduces major issues with regard to increased 
toxicity, increased clinical development times and, most 
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importantly, increased costs, which may make such logi-
cal approaches prohibitively expensive. Sandra Tuyaerts 
described plans for a revolutionary new study which aims 
to treat cervical, endometrial and uterine sarcoma with a 
combination based on many of the mechanisms already 
reviewed here. It aims to combine PD-1 blockade, radiation 
and several agents known to have favourable immune modu-
latory properties, such as CPA, lansoprazole, aspirin and 
vitamin D3. Assessment of the study primary endpoint will 
be performed using RECIST and immune-related response 
criteria at 26 weeks.
Thomas Nesselhut has long since expressed his views 
that carefully controlled observations can guide optimal 
immunotherapy development. (It is worth remembering 
that multiple chemotherapy for testes and lymphoma treat-
ment evolved without randomised studies!) He presented a 
number of cases, emphasising the benefit of enhancing the 
efficacy of his autologous DC-based vaccines using CPA 
(which agreed with many of the other presenters) the use 
of Newcastle disease virus (NDV) to prime DC vaccines, 
along with hyperthermia. (NDV is an oncolytic virus and 
hence this fits with data presented by A Melcher.) More 
recently, he has also been using NDV with Zometa plus 
gamma–delta T-cell treatment, which is entirely consistent 
with the data presented by Dan Fowler. He has also used 
low-dose naltrexone (LDN) as an immune stimulator, as has 
Julian Kenyon, who commented on its benefit in hundreds of 
patients he has treated anecdotally. This was of great interest 
as Rachel Cant (St George’s University of London, UK) 
reported on antagonism of TLRs 7, 8, and 9 by naltrexone, 
which could help explain the anti-inflammatory and immune 
stimulatory effects of LDN that are hard to explain based on 
its opiate receptor interaction above.
Concluding remarks
Many of these recurrent themes were discussed in detail 
in the final session, with a clear consensus on the need to 
optimise immunotherapy combinations and immune modu-
latory effects of chemotherapy, especially with regard to the 
use of CPA, which was mentioned by several speakers. The 
importance of biomarkers to help decide treatment options 
was agreed as important by many.
Bernard Fox raised the important potential of the micro-
biome and the effects of chemotherapy on gut inflammation 
and microbiome, as this is the focus of intense research by 
several established investigators.
Overall, the discussion paid homage to the memory of 
Holbrook Kohrt and his dramatic contribution to the field 
and pioneering contributions to combination immunother-
apy. In memory of this it was proposed that his legacy be 
honoured with a named lecture. Many people were asked to 
nominate the first Holbrook Kohrt lecture and the fact that 
both Bernard Fox and Paul Sondel came out on tie led to 
the decision to invite both of them to give named lectures 
in his honour.
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